WINNIPEG, MANITOBA--(Marketwire - November 29, 2007) - Miraculins Inc. (TSX VENTURE: MOM), a biotechnology company, dedicated to the discovery and development of diagnostic tools and therapeutic products for cancer, is pleased to announce that it is filing today, a pre-IDE (Investigational Device Exemption) submission with the U.S. Food and Drug Administration (FDA), in preparation for its planned clinical study for its P2V™ prostate cancer diagnostic test.
